One in eight men will develop prostate cancer in their lifetime. Surgery to treat the disease can lead to unwelcome side effects. A minimally invasive alternative that avoids surgery is now available ...

Koelis, SAS (“Koelis” or the “Company”, a global leader and innovator in MRI-ultrasound fusion guidance for prostate cancer interventions, announced today the official launch of its new software ...

It’s the second most common type of cancer among men and affects 1 in every 8 men in the United States. September is Prostate Cancer Awareness Month, and the American Cancer Society says this type of ...

Precisely delivered ultrasound could be an effective treatment for prostate cancer, with high-frequency sound waves heating and killing off cancer cells, a new study says. The treatment killed off all ...

Earlier this week, researchers presented data from the OPTIMUM (Optimization of Prostate Biopsy – Micro-Ultrasound Versus MRI) trial at the European Association of Urology Congress in Madrid, Spain.

Surgeon Dr. Daniel Costa, Associate Professor of Radiology at UT Southwestern Medical Center, tells KERA’s Sam Baker the new procedure uses ultrasound to destroy tumors in the prostate. How does the ...

An ultrasound-based treatment for prostate cancer showed better safety and operative metrics versus robotic radical prostatectomy in an early analysis of a first-ever randomized trial. After 6 months ...

Routine prostate cancer screenings save lives, yet some men still avoid them. However, making the process more streamlined increases the likelihood that men will get the tests they need to catch ...

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, is ...

Appointment signals next phase of expansion for HIFU-based prostate care as demand grows for non-invasive, ...

The 2 groups--those receiving ultra-hypofractionated radiotherapy and conventionally fractionated radiotherapy--had similar overall survival, which was 81% and 79%, respectively, at 10 years.